Breaking News Instant updates and real-time market news.

MYOV

Myovant Sciences

$12.02

-0.31 (-2.51%)

, TKPYY

Takeda Pharmaceutical

$24.21

0.05 (0.21%)

18:08
05/07/17
05/07
18:08
05/07/17
18:08

Myovant Sciences says Phase 2 relugolix study meets primary endpoint

Myovant Sciences (MYOV) announced the presentation of data from a placebo-controlled Phase 2 dose-finding study conducted by Takeda Pharmaceutical (TKPYY) evaluating the ability of relugolix to decrease heavy menstrual bleeding in women with uterine fibroids. The study met its primary endpoint with relugolix demonstrating a "marked decrease" in menstrual blood loss from Week 6 to Week 12 as assessed by a patient-reported outcome. The findings were presented during the Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists. Specifically, relugolix demonstrated statistical significance over placebo in the primary endpoint of the proportion of subjects who had reduction in menstrual blood loss from a score of at least 120 required at study entry to less than 10 from Week 6 through Week 12 on the Pictorial Blood Loss Assessment Chart. Relugolix decreased menstrual blood loss in a dose-dependent manner with the highest proportion of responses in the relugolix 40-mg group. In the relugolix 40-mg group, 73% of women achieved amenorrhea from Week 6 through Week 12. No women in the placebo group achieved amenorrhea. At Week 12, the 40-mg group demonstrated an absolute reduction in myoma and uterine volumes of approximately 50% from baseline compared to placebo. By Week 12, there was an increase in hemoglobin levels in the relugolix 20- and 40-mg groups compared to placebo. Patient-reported pain from uterine fibroids, based upon the numerical rating scale score, indicated that patients who received relugolix treatment had fewer pain symptoms from Week 6 to Week 12, with the relugolix 40-mg dose having the greatest reported reduction of pain symptoms. Bone mineral density decreased in a dose-dependent fashion with the greatest loss, -2.3%, observed in the relugolix 40-mg group. "These data provide a strong basis for our ongoing phase 3 studies, LIBERTY 1 & 2," the company remarked.

MYOV

Myovant Sciences

$12.02

-0.31 (-2.51%)

TKPYY

Takeda Pharmaceutical

$24.21

0.05 (0.21%)

MYOV Myovant Sciences
$12.02

-0.31 (-2.51%)

11/21/16
BARD
11/21/16
INITIATION
Target $20
BARD
Outperform
Myovant Sciences initiated with an Outperform at Baird
Baird analyst Brian Skorney initiated Myovant Sciences with an Outperform and a $20 price target.
11/21/16
SBSH
11/21/16
INITIATION
Target $17
SBSH
Buy
Myovant Sciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Myovant Sciences (MYOV) with a Buy rating and $17 price target. The analyst sees upside if the company meets enrollment timelines through 2017. Myovant's Relagolix is validated by Neurocrine's (NBIX) Elagolix, but may have greater convenience and efficacy, Karnauskas contends.
11/21/16
COWN
11/21/16
INITIATION
Target $11
COWN
Outperform
Myovant Sciences initiated with an Outperform at Cowen
Cowen analyst Phil Nadeau initiated Myovant Sciences with an Outperform rating and $11 price target as he believes its Relugolix drug potential is undervalued. He noted it reported a strong proof of concept and should enter pivotal programs in 1H 2017, while projecting peak sales of more than $2B.
11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TKPYY Takeda Pharmaceutical
$24.21

0.05 (0.21%)

01/11/17
RHCO
01/11/17
DOWNGRADE
RHCO
Hold
ARIAD downgraded following deal at SunTrust
As noted earlier, SunTrust downgraded ARIAD (ARIA) to Hold from Buy. Analyst Yatin Suneja downgraded the shares after the company agreed to be acquired by Takeda (TKPYY). The analyst expects the deal to close. Target to $24 from $22.
01/17/17
PIPR
01/17/17
NO CHANGE
Target $15
PIPR
Overweight
Array BioPharma strength likely aided by M&A speculation, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Array BioPharma (ARRY) shares hit a 52-week high during Friday's trading, which he attributes to M&A speculation following Ariad's (ARIA) agreement to be acquired by Takeda (TKPYY). Tenthoff, who sees several business development opportunities for Array, reiterates his Overweight rating and $15 price target on the shares.
01/31/17
01/31/17
NO CHANGE

Exelixis down with licensing deal seen as impacting takeover potential
Shares of Exelixis (EXEL) are moving lower after the company last night announced a licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, its oncology medicine, with Takeda Pharmaceutical (TKPYY). Deutsche Bank analyst Andrew Peters said earlier today that while Exelixis' licensing agreement is "clearly encouraging" and highlights the value of cabozantinib, the news could impact "near-term expectations regarding strategic activity, as Japanese rights would be similarly valuable to maintain." Exelixis is down 4%, or 66c, to $17.62 in afternoon trading, a sign that the deal with Takeda could be dampening investor expectations of a buyout in the near-term. The company maintaining the U.S. rights is key, Peters told investors in a research note, adding that the U.S. is core to the valuation and the company's strategic positioning. The analyst has a Buy rating on Exelixis with a $20 price target.
02/06/17
02/06/17
UPGRADE
Target $67

Outperform
PRA Health upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Erin Wilson Wright upgraded PRA Health (PRAH) to Outperform from Neutral on greater enthusiasm for the company's recent partnership with Takeda (TKPYY), an incrementally more positive outlook for the broader functional outsourcing market, and relatively healthy CRO industry fundamentals. The analyst also raised her price target on PRA Health's shares to $67 from $50.

TODAY'S FREE FLY STORIES

INTU

Intuit

$190.41

-1.33 (-0.69%)

21:46
05/22/18
05/22
21:46
05/22/18
21:46
Downgrade
Intuit rating change  »

Intuit downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 12

    Jun

SPY

SPDR S&P 500 ETF Trust

$272.57

-0.69 (-0.25%)

, SPX

S&P 500

$0.00

(0.00%)

21:05
05/22/18
05/22
21:05
05/22/18
21:05
Periodicals
Trump to propose further tax cuts before November, Reuters reports »

President Trump has…

SPY

SPDR S&P 500 ETF Trust

$272.57

-0.69 (-0.25%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$42.26

-1.36 (-3.12%)

20:49
05/22/18
05/22
20:49
05/22/18
20:49
Syndicate
FB Financial 3.2M share Secondary priced at $41.25 »

JPMorgan and Stephens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 24

    Sep

  • 23

    May

MYOK

MyoKardia

$50.45

2.15 (4.45%)

20:48
05/22/18
05/22
20:48
05/22/18
20:48
Syndicate
MyoKardia 3.75M share Secondary priced at $49.00 »

JPMorgan, BofA/Merrill,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

TWOU

2U

$91.64

-3.86 (-4.04%)

20:47
05/22/18
05/22
20:47
05/22/18
20:47
Syndicate
2U 3.3M share Secondary priced at $90.00 »

Goldman Sachs and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ARDX

Ardelyx

$4.50

-1.15 (-20.35%)

20:46
05/22/18
05/22
20:46
05/22/18
20:46
Syndicate
Ardelyx 12.5M share Secondary priced at $4.00 »

Jefferies and Leerink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

  • 23

    May

LOW

Lowe's

$85.74

-1.63 (-1.87%)

, TGT

Target

$75.42

-1.44 (-1.87%)

20:25
05/22/18
05/22
20:25
05/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$85.74

-1.63 (-1.87%)

TGT

Target

$75.42

-1.44 (-1.87%)

TIF

Tiffany

$102.26

-0.96 (-0.93%)

RL

Ralph Lauren

$116.67

-0.41 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 07

    Jun

  • 19

    Jun

  • 26

    Jun

INFO

IHS Markit

$51.28

-0.32 (-0.62%)

20:02
05/22/18
05/22
20:02
05/22/18
20:02
Hot Stocks
IHS Markit expands MarkitSERV trade reporting solution in Asia and Europe »

IHS Markit (INFO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDAY

Ceridian

$34.31

-0.885 (-2.51%)

19:54
05/22/18
05/22
19:54
05/22/18
19:54
Recommendations
Ceridian analyst commentary at MUFG »

Ceridian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

RMTI

Rockwell Medical

$5.94

-0.06 (-1.00%)

19:20
05/22/18
05/22
19:20
05/22/18
19:20
Hot Stocks
Rockwell Medical president, CEO Chioini terminated from his positions »

Rockwell Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,582.10

-3.45 (-0.22%)

19:16
05/22/18
05/22
19:16
05/22/18
19:16
Periodicals
Amazon.com has banned some shoppers who make excessive returns, WSJ says »

Amazon.com has banned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

CTRP

Ctrip

$43.46

0.48 (1.12%)

, HPE

HP Enterprise

$17.49

-0.01 (-0.06%)

19:03
05/22/18
05/22
19:03
05/22/18
19:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ctrip…

CTRP

Ctrip

$43.46

0.48 (1.12%)

HPE

HP Enterprise

$17.49

-0.01 (-0.06%)

ARCO

Arcos Dorados

$7.55

0.35 (4.86%)

MET

MetLife

$48.48

0.405 (0.84%)

RRGB

Red Robin

$57.80

-2.9 (-4.78%)

TCS

Container Store

$8.23

0.68 (9.01%)

URBN

Urban Outfitters

$41.21

-1.09 (-2.58%)

CRIS

Curis

$0.53

0.0211 (4.13%)

IBTX

Independent Bank

$77.85

-0.7 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 30

    May

  • 05

    Jun

  • 11

    Jun

  • 12

    Jun

  • 10

    Jul

  • 10

    Sep

  • 24

    Sep

EADSY

Airbus

$0.00

(0.00%)

, BA

Boeing

$355.06

-8.89 (-2.44%)

18:59
05/22/18
05/22
18:59
05/22/18
18:59
Periodicals
Airbus says plane subsidies over, U.S. rejects notion, WSJ says »

The U.S. and EU have…

EADSY

Airbus

$0.00

(0.00%)

BA

Boeing

$355.06

-8.89 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

QTNA

Quantenna Communications

$14.94

-0.13 (-0.86%)

18:43
05/22/18
05/22
18:43
05/22/18
18:43
Initiation
Quantenna Communications initiated at William Blair »

Quantenna assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

ALGT

Allegiant Travel

$153.95

-5.15 (-3.24%)

18:42
05/22/18
05/22
18:42
05/22/18
18:42
Hot Stocks
Allegiant Travel announces tentative dispatchers contract agreement with IBT »

Allegiant announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

EA

Electronic Arts

$132.18

-0.73 (-0.55%)

18:30
05/22/18
05/22
18:30
05/22/18
18:30
Recommendations
Electronic Arts analyst commentary at Baird »

Electronic Arts'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POOL

Pool Corp.

$145.96

-3.74 (-2.50%)

18:22
05/22/18
05/22
18:22
05/22/18
18:22
Hot Stocks
Pool Corp. director Stokely sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

  • 13

    Jun

RRGB

Red Robin

$57.80

-2.9 (-4.78%)

18:16
05/22/18
05/22
18:16
05/22/18
18:16
Recommendations
Red Robin analyst commentary at Stephens »

Red Robin Q1 traffic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

BGS

B&G Foods

$26.50

-0.75 (-2.75%)

18:11
05/22/18
05/22
18:11
05/22/18
18:11
Hot Stocks
B&G Foods increases dividend 2.2% to 47.5c »

B&G Foods announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CTRP

Ctrip

$43.46

0.48 (1.12%)

18:05
05/22/18
05/22
18:05
05/22/18
18:05
Hot Stocks
Breaking Hot Stocks news story on Ctrip »

Ctrip falls over 3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

CTRP

Ctrip

$43.46

0.48 (1.12%)

18:05
05/22/18
05/22
18:05
05/22/18
18:05
Earnings
Ctrip reports Q1 adjusted earnings per ADS 55c, may not compare to consensus 16c »

Reports Q1 revenue $1.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

PLBC

Plumas Bancorp

$28.00

(0.00%)

18:02
05/22/18
05/22
18:02
05/22/18
18:02
Hot Stocks
Plumas Bank agrees to purchase Carson City branch of Mutual of Omaha Bank »

Plumas Bank, the wholly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$43.46

0.48 (1.12%)

18:02
05/22/18
05/22
18:02
05/22/18
18:02
Earnings
Breaking Earnings news story on Ctrip »

Ctrip sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

CRIS

Curis

$0.53

0.0211 (4.13%)

17:56
05/22/18
05/22
17:56
05/22/18
17:56
Hot Stocks
Curis announces 1-for-5 reverse stock split »

Curis announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCS

Container Store

$8.23

0.68 (9.01%)

17:47
05/22/18
05/22
17:47
05/22/18
17:47
Hot Stocks
Container Store drops 12% after Q4 EPS lower than estimates »

Shares of the Container…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.